摘要
Abstract
Objective:To investigate the efficacy and safety of Calcitriol in the treatment of secondary hyperparathyroidism(SHPT) following long-term hemodialysis.Method:A total of 69 patients at end stage renal disease that required maintenance hemodialysis were enrolled into this clinical trial during the period from Feb 2013 to Apr 2014 at Suzhou Xiangcheng People’s Hospital.Serum levels of calcium,phosphorus,and iPTH were assayed for patients treated with Calcitriol prior to treatment and 4 weeks,8 weeks,12 weeks,and 24 weeks to investigate changes in these parameters.Result:When compared to pre-treatment,the serum level of iPTH for all subjects was decreased after Calcitriol treatment for 4 weeks,8 weeks,12 weeks,and 24 weeks,there were significantly differences between 8 weeks,12 weeks,24 weeks and before treatment(P<0.05).After 24 weeks’ treatment of Calcitriol,iPTH level in 52 subjects was down regulated to the targeted levels with an effective rate of 75.4%.After treatment,serum level of calcium in all subjects was observed increased slightly but with no significant difference(P>0.05).Conclusion:It is concluded that Calcitriol is beneficial and safety in the treatment of secondary hyperparathyroidism following long-term hemodialysis.关键词
慢性肾功能衰竭/骨化三醇/继发性甲状旁腺素功能亢进/罗盖全Key words
Chronic renal failure/Calcitriol/Secondary hyperparathyroidism/Rocaltrol分类
医药卫生
